表紙
市場調査レポート

Agios Pharmaceuticals, Inc.:製品パイプライン分析

Agios Pharmaceuticals, Inc. - Product Pipeline Review - 2015

発行 Global Markets Direct 商品コード 253798
出版日 ページ情報 英文 37 Pages
即納可能
価格
本日の銀行送金レート: 1USD=105.42円で換算しております。
Back to Top
Agios Pharmaceuticals, Inc.:製品パイプライン分析 Agios Pharmaceuticals, Inc. - Product Pipeline Review - 2015
出版日: 2015年10月21日 ページ情報: 英文 37 Pages
概要

Agios Pharmaceuticals, Inc.は、癌代謝の領域で治療薬を開発しているバイオ製薬会社です。同社は癌の治療、解糖、脂肪酸の代謝、自食作用に焦点を当てた薬剤の開発を進めています。同社製品は自己免疫性、炎症性、神経系の各疾患の治療に使われています。

当レポートでは、Agios Pharmaceuticals, Inc.の治療薬開発パイプラインの現況と最新アップデートによる各開発段階の比較分析、企業や研究機関によって開発中の治療薬、治療薬の評価、後期段階および中止されたプロジェクトに関する情報などを最新のニュースや発表も交えて提供しています。

Agios Pharmaceuticals, Inc.の基本情報

  • Agios Pharmaceuticals, Inc.の概要
  • 主要情報
  • 企業情報

Agios Pharmaceuticals, Inc.:R&Dの概要

  • 主な治療範囲

Agios Pharmaceuticals, Inc.:パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品
  • アウトライセンス製品
    • アウトライセンス製品/併用療法モダリティ

Agios Pharmaceuticals, Inc.:パイプライン製品の概況

  • 治験段階にあるパイプライン製品
    • 第I相にある製品/併用療法モダリティ
  • 初期段階にあるパイプライン製品
    • 前臨床段階にある製品/併用療法モダリティ
    • 創薬中の製品/併用療法モダリティ

Agios Pharmaceuticals, Inc.:薬剤プロファイル

  • AG-120
  • AG-348
  • AGI-14100
  • CM-4
  • Small Molecule to Inhibit PKM2 for Cancer
  • Small Molecules For Inborn Errors Of Metabolism
  • Small Molecules to Inhibit Glutaminase for Cancer

Agios Pharmaceuticals, Inc.:パイプライン分析

  • 標的別
  • 投与経路別
  • 分子タイプ別
  • 作用機序別

Agios Pharmaceuticals, Inc.:最近のパイプライン動向

Agios Pharmaceuticals, Inc.:休止中のプロジェクト

Agios Pharmaceuticals, Inc.:本社と子会社の所在地

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC07675CDB

Summary

Global Markets Direct's, 'Agios Pharmaceuticals, Inc. - Product Pipeline Review - 2015', provides an overview of the Agios Pharmaceuticals, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Agios Pharmaceuticals, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Agios Pharmaceuticals, Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Agios Pharmaceuticals, Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Agios Pharmaceuticals, Inc.'s pipeline products

Reasons to buy

  • Evaluate Agios Pharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Agios Pharmaceuticals, Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Agios Pharmaceuticals, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Agios Pharmaceuticals, Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Agios Pharmaceuticals, Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Agios Pharmaceuticals, Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Agios Pharmaceuticals, Inc. Snapshot
    • Agios Pharmaceuticals, Inc. Overview
    • Key Information
    • Key Facts
  • Agios Pharmaceuticals, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Agios Pharmaceuticals, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • Agios Pharmaceuticals, Inc. - Pipeline Products Glance
    • Agios Pharmaceuticals, Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Agios Pharmaceuticals, Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Agios Pharmaceuticals, Inc. - Drug Profiles
    • AG-348
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AG-120
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AG-881
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AGI-14100
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CM-4
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Activate PKM2 for Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules for Inborn Errors Of Metabolism
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit Glutaminase for Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Agios Pharmaceuticals, Inc. - Pipeline Analysis
    • Agios Pharmaceuticals, Inc. - Pipeline Products by Target
    • Agios Pharmaceuticals, Inc. - Pipeline Products by Route of Administration
    • Agios Pharmaceuticals, Inc. - Pipeline Products by Molecule Type
    • Agios Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action
  • Agios Pharmaceuticals, Inc. - Recent Pipeline Updates
  • Agios Pharmaceuticals, Inc. - Dormant Projects
  • Agios Pharmaceuticals, Inc. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Agios Pharmaceuticals, Inc., Key Information
  • Agios Pharmaceuticals, Inc., Key Facts
  • Agios Pharmaceuticals, Inc. - Pipeline by Indication, 2015
  • Agios Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2015
  • Agios Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2015
  • Agios Pharmaceuticals, Inc. - Out-Licensed Products in Pipeline, 2015
  • Agios Pharmaceuticals, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2015
  • Agios Pharmaceuticals, Inc. - Phase II, 2015
  • Agios Pharmaceuticals, Inc. - Phase I, 2015
  • Agios Pharmaceuticals, Inc. - Preclinical, 2015
  • Agios Pharmaceuticals, Inc. - Discovery, 2015
  • Agios Pharmaceuticals, Inc. - Pipeline by Target, 2015
  • Agios Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2015
  • Agios Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2015
  • Agios Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2015
  • Agios Pharmaceuticals, Inc. - Recent Pipeline Updates, 2015
  • Agios Pharmaceuticals, Inc. - Dormant Developmental Projects,2015

List of Figures

  • Agios Pharmaceuticals, Inc. - Pipeline by Top 10 Indication, 2015
  • Agios Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2015
  • Agios Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2015
  • Agios Pharmaceuticals, Inc. - Out-Licensed Products in Pipeline, 2015
  • Agios Pharmaceuticals, Inc. - Pipeline by Top 10 Target, 2015
  • Agios Pharmaceuticals, Inc. - Pipeline by Top 10 Route of Administration, 2015
  • Agios Pharmaceuticals, Inc. - Pipeline by Top 10 Molecule Type, 2015
  • Agios Pharmaceuticals, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top